ArticlePain reports2026
Protective effect of new histone deacetylase 6 inhibitors in a cisplatin-induced peripheral neurotoxicity murine model.
Article in Pain reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microtubule Cytoskeleton Dysfunction in Chronic Pain: Mechanisms of Transport Failure and Emerging Therapeutic Targets.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Histone deacetylase 6 (HDAC6) inhibitors have shown effectiveness in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN), a severe side effect of various antineoplastic drugs, with no available preventive or therapeutic treatments. This study presents in vivo results for ITF6464 and ITF6475, 2 HDAC6 inhibitors featuring a difluoromethyloxadiazole (DFMO), zinc-binding group ensuring selectivity for HDAC6. Objectives: This study investigated the potential effect of 2 new selective DFMO HDAC6 inhibitors in preventive and curative settings in a well-established CIPN model. Methods: The effectiveness of treatments was evaluated by dynamic test and histological analysis on dorsal root ganglia (DRG) and skin biopsy. The acetylation of tubulin was also investigated in sciatic nerve by western blot. Results: ITF6464 and ITF6475 administered at 12.5 mg/kg dose prevented cisplatin-induced mechanical allodynia (*** Conclusions: These studies highlight the potential of the new selective HDAC6 inhibitors ITF6464 and ITF6475 as promising treatments for CIPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.